246 related articles for article (PubMed ID: 34504265)
1. Irinotecan and its metabolite SN38 inhibits procollagen I production of dermal fibroblasts from Systemic Sclerosis patients.
Lapoirie J; Tran L; Piazza L; Contin-Bordes C; Truchetet ME; Bonnet F
Sci Rep; 2021 Sep; 11(1):18011. PubMed ID: 34504265
[TBL] [Abstract][Full Text] [Related]
2. Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts.
Brembilla NC; Montanari E; Truchetet ME; Raschi E; Meroni P; Chizzolini C
Arthritis Res Ther; 2013 Oct; 15(5):R151. PubMed ID: 24289089
[TBL] [Abstract][Full Text] [Related]
3. Effects of the immunosuppressant rapamycin on the expression of human α2(I) collagen and matrix metalloproteinase 1 genes in scleroderma dermal fibroblasts.
Tamaki Z; Asano Y; Kubo M; Ihn H; Tada Y; Sugaya M; Kadono T; Sato S
J Dermatol Sci; 2014 Jun; 74(3):251-9. PubMed ID: 24630239
[TBL] [Abstract][Full Text] [Related]
4. The inhibitory effects of camptothecin, a topoisomerase I inhibitor, on collagen synthesis in fibroblasts from patients with systemic sclerosis.
Czuwara-Ladykowska J; Makiela B; Smith EA; Trojanowska M; Rudnicka L
Arthritis Res; 2001; 3(5):311-8. PubMed ID: 11549373
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors.
Kawaguchi Y; Takagi K; Hara M; Fukasawa C; Sugiura T; Nishimagi E; Harigai M; Kamatani N
Arthritis Rheum; 2004 Jan; 50(1):216-26. PubMed ID: 14730619
[TBL] [Abstract][Full Text] [Related]
6. CXCL17-mediated downregulation of type I collagen via MMP1 and miR-29 in skin fibroblasts possibly contributes to the fibrosis in systemic sclerosis.
Shimada S; Makino K; Jinnin M; Sawamura S; Kawano Y; Ide M; Kajihara I; Makino T; Fukushima S; Ihn H
J Dermatol Sci; 2020 Dec; 100(3):183-191. PubMed ID: 33055012
[TBL] [Abstract][Full Text] [Related]
7. B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis.
François A; Chatelus E; Wachsmann D; Sibilia J; Bahram S; Alsaleh G; Gottenberg JE
Arthritis Res Ther; 2013 Oct; 15(5):R168. PubMed ID: 24289101
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of the transforming growth factor β-inducible gene HIC-5 in systemic sclerosis skin and fibroblasts: a novel antifibrotic therapeutic target.
Piera-Velazquez S; Fertala J; Huaman-Vargas G; Louneva N; Jiménez SA
Rheumatology (Oxford); 2020 Oct; 59(10):3092-3098. PubMed ID: 32442272
[TBL] [Abstract][Full Text] [Related]
9. Ciprofloxacin has antifibrotic effects in scleroderma fibroblasts via downregulation of Dnmt1 and upregulation of Fli1.
Bujor AM; Haines P; Padilla C; Christmann RB; Junie M; Sampaio-Barros PD; Lafyatis R; Trojanowska M
Int J Mol Med; 2012 Dec; 30(6):1473-80. PubMed ID: 23041765
[TBL] [Abstract][Full Text] [Related]
10. 2-Methoxyestradiol inhibits bleomycin-induced systemic sclerosis through suppression of fibroblast activation.
Zhu L; Song Y; Li M
J Dermatol Sci; 2015 Jan; 77(1):63-70. PubMed ID: 25465161
[TBL] [Abstract][Full Text] [Related]
11. Akt blockade downregulates collagen and upregulates MMP1 in human dermal fibroblasts.
Bujor AM; Pannu J; Bu S; Smith EA; Muise-Helmericks RC; Trojanowska M
J Invest Dermatol; 2008 Aug; 128(8):1906-14. PubMed ID: 18323784
[TBL] [Abstract][Full Text] [Related]
12. Role of endothelin-1 in the skin fibrosis of systemic sclerosis.
Jing J; Dou TT; Yang JQ; Chen XB; Cao HL; Min M; Cai SQ; Zheng M; Man XY
Eur Cytokine Netw; 2015; 26(1):10-4. PubMed ID: 25990837
[TBL] [Abstract][Full Text] [Related]
13. Modulation by 17,20S(OH)
Brown Lobbins ML; Slominski AT; Hasty KA; Zhang S; Miller DD; Li W; Kim TK; Janjetovic Z; Tuckey RC; Scott IO; Myers LK; Postlethwaite AE
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008794
[TBL] [Abstract][Full Text] [Related]
14. Antifibrotic effects of crocetin in scleroderma fibroblasts and in bleomycin-induced sclerotic mice.
Song Y; Zhu L; Li M
Clinics (Sao Paulo); 2013 Oct; 68(10):1350-7. PubMed ID: 24212843
[TBL] [Abstract][Full Text] [Related]
15. Scleroderma keratinocytes promote fibroblast activation independent of transforming growth factor beta.
McCoy SS; Reed TJ; Berthier CC; Tsou PS; Liu J; Gudjonsson JE; Khanna D; Kahlenberg JM
Rheumatology (Oxford); 2017 Nov; 56(11):1970-1981. PubMed ID: 28968684
[TBL] [Abstract][Full Text] [Related]
16. Parvovirus B19 activates in vitro normal human dermal fibroblasts: a possible implication in skin fibrosis and systemic sclerosis.
Arvia R; Margheri F; Stincarelli MA; Laurenzana A; Fibbi G; Gallinella G; Ferri C; Del Rosso M; Zakrzewska K
Rheumatology (Oxford); 2020 Nov; 59(11):3526-3532. PubMed ID: 32556240
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis.
Distler O; Pap T; Kowal-Bielecka O; Meyringer R; Guiducci S; Landthaler M; Schölmerich J; Michel BA; Gay RE; Matucci-Cerinic M; Gay S; Müller-Ladner U
Arthritis Rheum; 2001 Nov; 44(11):2665-78. PubMed ID: 11710722
[TBL] [Abstract][Full Text] [Related]
18. The fibrotic phenotype of systemic sclerosis fibroblasts varies with disease duration and severity of skin involvement: reconstitution of skin fibrosis development using a tissue engineering approach.
Corriveau MP; Boufaied I; Lessard J; Chabaud S; Senécal JL; Grodzicky T; Chartier S; Raymond Y; Moulin VJ
J Pathol; 2009 Mar; 217(4):534-42. PubMed ID: 19086038
[TBL] [Abstract][Full Text] [Related]
19. [Inhibition effects of constituents of Radix Salviae Miltiorrhizae on proliferation and procollagen transcription of dermal fibroblasts in systemic sclerosis].
Lü XY; Li M; Weng MW
Zhonghua Yi Xue Za Zhi; 2007 Sep; 87(34):2426-8. PubMed ID: 18036324
[TBL] [Abstract][Full Text] [Related]
20. Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1.
Akamata K; Asano Y; Aozasa N; Noda S; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sato S
Arthritis Res Ther; 2014 Apr; 16(2):R86. PubMed ID: 24708674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
